Cargando…

2532. Pharmacokinetic-Pharmacodynamic Analyses for Ceftobiprole Efficacy Based on Phase 3 Data from Patients with Staphylococcus aureus Bacteremia

BACKGROUND: Ceftobiprole medocaril is an intravenously (IV) administered cephalosporin prodrug that is rapidly converted in vivo to ceftobiprole, which has activity against Gram-positive and Gram-negative organisms. Ceftobiprole is being developed for the treatment of patients with S. aureus bactere...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhavnani, Sujata M, Hammel, Jeffrey P, Liolios, Kathryn, Cammarata, Anthony P, Saulay, Mikael, Rubino, Christopher M, Engelhardt, Marc, Smart, Jennifer, Jones, Mark E, Ambrose, Paul G, Litherland, Karine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677510/ http://dx.doi.org/10.1093/ofid/ofad500.2150

Ejemplares similares

2531. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Dosing Regimens for Patients with Staphylococcus aureus Bacteremia (SAB)
por: Bhavnani, Sujata M, et al.
Publicado: (2023)

2561. Population Pharmacokinetic Analyses for Ceftobiprole Using Data from Phase 1 and 3 Studies
por: Cammarata, Anthony P, et al.
Publicado: (2023)

2530. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Dose Selection for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and Community-Acquired Bacterial Pneumonia (CABP)
por: Bhavnani, Sujata M, et al.
Publicado: (2023)

LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baumannii-calcoaceticus Complex (ABC) Infections
por: Bhavnani, Sujata M, et al.
Publicado: (2022)

Model-Based Approach for Optimizing Ceftobiprole Dosage in Pediatric Patients
por: Rubino, Christopher M., et al.
Publicado: (2021)

Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: a novel protocol for a double-blind, Phase III trial
por: Hamed, Kamal, et al.
Publicado: (2020)

Pharmacokinetics and Safety of Ceftobiprole in Pediatric Patients
por: Rubino, Christopher M., et al.
Publicado: (2021)

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints
por: Bhavnani, S. M., et al.
Publicado: (2022)

733. Pharmacokinetic–Pharmacodynamic (PK–PD) Analyses for Alanine Aminotransferase (ALT) Using Phase 3 Data From Omadacycline (OMC)-Treated Patients
por: Bhavnani, Sujata M, et al.
Publicado: (2019)

Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia
por: Bhavnani, Sujata M, et al.
Publicado: (2019)

1392. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Inhaled ME1100 Dose Selection
por: Bhavnani, Sujata M, et al.
Publicado: (2018)

Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials
por: Scheeren, Thomas W. L., et al.
Publicado: (2019)

Pharmacokinetics, pharmacodynamics, and safety of single- and multiple-dose intravenous ceftobiprole in healthy Chinese participants
por: Li, Wan-Zhen, et al.
Publicado: (2021)

Pharmacokinetics and Target Attainment of Ceftobiprole in Asian and Non‐Asian Subjects
por: Muller, A. E., et al.
Publicado: (2018)

Getting it Right the First Time: Relating Pharmacokinetic-Pharmacodynamic Target Attainment and Patient Outcomes
por: Bulik, Catharine C, et al.
Publicado: (2017)

1390. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of Candida
por: Lakota, Elizabeth A, et al.
Publicado: (2018)

A Phase 3, Randomized, Investigator-blinded Trial Comparing Ceftobiprole With a Standard-of-care Cephalosporin, With or Without Vancomycin, for the Treatment of Pneumonia in Pediatric Patients
por: Bosheva, Miroslava, et al.
Publicado: (2021)

2562. Re-Appraisal of Aminoglycoside (AG) Susceptibility Testing Breakpoints Based on the Application of Pharmacokinetics–Pharmacodynamics (PK-PD) and Contemporary Microbiology Surveillance Data
por: Bhavnani, Sujata M, et al.
Publicado: (2018)

Ceftobiprole: pharmacokinetics and PK/PD profile
por: Azanza Perea, José Ramón, et al.
Publicado: (2019)

2568. Characterization of Sulopenem Pharmacokinetics-Pharmacodynamics Using a One-Compartment In Vitro Infection Model
por: VanScoy, Brian D, et al.
Publicado: (2023)

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata
por: Bader, Justin C., et al.
Publicado: (2018)

1946. In Vitro Activity of Ceftobiprole against Staphylococcus aureus Bacteremia Isolates from the United States (2018–2020)
por: Duncan, Leonard R, et al.
Publicado: (2023)

At the Crossroads of Stewardship and Technology: Impact of Pharmacokinetic-Pharmacodynamic (PK-PD) Integrated Electronic Decision Support Software (EDSS) on the Treatment of Patients Infected with Pneumonia
por: Bader, Justin C, et al.
Publicado: (2017)

1304. Characterization of Tebipenem Pivoxil Hydrobromide Pharmacokinetics-Pharmacodynamics (PK-PD) in a Neutropenic Murine Acute Pyelonephritis (AP) Model
por: VanScoy, Brian D, et al.
Publicado: (2020)

Ceftobiprole Medocaril Is an Effective Post-Exposure Treatment in the Fischer 344 Rat Model of Pneumonic Tularemia
por: Hahn, Mark M., et al.
Publicado: (2023)

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae
por: Bhavnani, Sujata M., et al.
Publicado: (2023)

2549. Pharmacometric Analyses to Support Sulbactam-Durlobactam (SUL-DUR) Dosing Regimens in Patients with Altered Renal Function
por: Larson, Kajal, et al.
Publicado: (2023)

Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET)
por: Overcash, J Scott, et al.
Publicado: (2020)

The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus Acinetobacter baumannii-calcoaceticus Complex
por: O’Donnell, John P, et al.
Publicado: (2023)

2569. Pharmacokinetic-Pharmacodynamic Evaluation of Sulopenem Using a Five-Day Hollow-Fiber In Vitro Infection Model
por: VanScoy, Brian D, et al.
Publicado: (2023)

Ceftobiprole medocaril
por: Méndez, Raúl, et al.
Publicado: (2022)

2532: Predictive metabolism studies of varenicline and implications of its metabolites in nicotine addiction
por: Thompson, Keeshaloy, et al.
Publicado: (2018)

Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using a One-Compartment In Vitro Infection Model
por: VanScoy, Brian D., et al.
Publicado: (2020)

Gepotidacin Pharmacokinetics-Pharmacodynamics against Escherichia coli in the One-Compartment and Hollow-Fiber In Vitro Infection Model Systems
por: VanScoy, Brian D., et al.
Publicado: (2021)

Safety and tolerability of ceftobiprole
por: Grau, Santiago
Publicado: (2019)

Ceftobiprole for the treatment of pneumonia
por: Cillóniz, Catia, et al.
Publicado: (2019)

2532. Identifying Educational Needs and Improving Provider Knowledge Regarding the Management of Febrile Neutropenia
por: Chang, Amy, et al.
Publicado: (2019)

593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
por: Ganesan, Harish, et al.
Publicado: (2022)

2785. Characterization of Methicillin-resistant Staphylococcus aureus Bloodstream Isolates Recovered from Patients Enrolled in a Randomized, Double-blind, Multi-center Study to Establish the Efficacy and Safety of Ceftobiprole for Treatment of Bacteremia, Including Infective Endocarditis
por: Mendes, Rodrigo E, et al.
Publicado: (2023)

Pharmacokinetic/pharmacodynamic parameters of vancomycin for predicting clinical outcome of enterococcal bacteremia
por: Nham, Eliel, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b9acsr1ct5blnqcbrddc4314m6